Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 26, 1337-1343, July 1, 1966]
© 1966 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kimball, A. P.
Right arrow Articles by LePage, G. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kimball, A. P.
Right arrow Articles by LePage, G. A.

Inhibitory Effects of the Arabinosides of 6-Mercaptopurine and Cytosine on Purine and Pyrimidine Metabolism1

A. P. Kimball, B. Bowman, P. S. Bush, J. Herriot and G. A. LePage

Life Sciences Research, Stanford Research Institute, Menlo Park, California

The influences on metabolism in ascites tumor cells of azaserine, 1-ß-D-arabinofuranosylcytosine (ara-C),2 and 9-ß-D-arabinofuranosyl-9-H-purine-6-thiol (ara-6-MP) were studied and compared. Either ara-C or azaserine blocked the incorporation of purine and pyrimidine precursors into DNA. Survival studies indicated that a combination of the 2 gave an additive response. Either ara-C or ara-6-MP blocked the conversion of cytidylate to deoxycytidylate. Treatment of tumor-bearing mice with a combination of ara-C and ara-6-MP gave an additive response. Azaserine blocked the conversion of uridylate to cytidylate. Combination therapy with azaserine and ara-6-MP gave a synergistic response. The drug synergism given by combinations of azaserine and ara-6-MP suggests that a sequential block occurs in the formation of deoxycytidylate from uridylate.

1 This work was supported by Contract PH 43-65-575 with the Cancer Chemotherapy National Service Center, National Cancer Institute, NIH.

2 Abbreviations used: ara-C, 1-ß-D-arabinofuranosylcytosine; ara-6-MP, 9-ß-D-arabinofuranosyl-9-H-purine-6-thiol; 6-MP, 6-metcaptopurine; TPNH, reduced triphosphopyridine nucleotide; ATP, adenosine-5'-triphosphate; AMP, adenosine-5'-monophosphate; dAMP, 5'-deoxyadenylate; GMP, 5'-guanylate; dGMP; 5'-deoxyguanylate; UMP, 5'-uridylate; dUMP, 5'-deoxyuridylate; TMP, 5'-thymidylate; CMP, 5'-cytidylate; dCMP, 5'-deoxycytidylate; aza, azaserine.

Received 10/22/65.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1966 by the American Association for Cancer Research.